Project List

HTTP 200 OK
  Allow: GET, HEAD, OPTIONS
  Content-Type: application/json
  Vary: Accept
  
  {
    "count": 2213,
    "next": "https://api-test.medunigraz.at/v1/research/project/?format=api&limit=20&offset=2100&ordering=-end_planned",
    "previous": "https://api-test.medunigraz.at/v1/research/project/?format=api&limit=20&offset=2060&ordering=-end_planned",
    "results": [
        {
            "id": 2034,
            "title": {
                "de": "Analyse von Zytokin-Genpolymorphismen bei Patienten mit retinalem nichtentzündlichen Arterienverschluss",
                "en": "Analyse von Zytokin-Genpolymorphismen bei Patienten mit retinalem nichtentzündlichen Arterienverschluss"
            },
            "short": "ZYTOKIN_GENPOLYMORPHISMEN_ARTERIEN",
            "url": null,
            "abstract": {
                "de": null,
                "en": null
            },
            "begin_planned": "2009-06-01T02:00:00+02:00",
            "begin_effective": "2009-06-01T02:00:00+02:00",
            "end_planned": "2009-12-31T01:00:00+01:00",
            "end_effective": "2009-12-31T01:00:00+01:00",
            "assignment": "2010-01-12T18:03:24+01:00",
            "program": null,
            "subprogram": null,
            "organization": 14043,
            "category": 10,
            "type": 10,
            "partner_function": 4,
            "manager": 51984,
            "contact": null,
            "status": 2,
            "research": 2,
            "grant": 10,
            "event": null,
            "study": null,
            "language": null,
            "funders": [
                938
            ],
            "funder_projectcode": null,
            "ethics_committee": null,
            "edudract_number": null,
            "persons": [
                "2034-51984-10"
            ]
        },
        {
            "id": 2118,
            "title": {
                "de": "Antitumor-Aktivität bioaktiver Wirkstoffe in chemoresistenten Tumoren: Apoptose in Medullären Schilddrüsencarcinomen",
                "en": "Antitumor-Aktivität bioaktiver Wirkstoffe in chemoresistenten Tumoren: Apoptose in Medullären Schilddrüsencarcinomen"
            },
            "short": "APOPTOSE_MEDULL_SCHILDDRÜSCARC",
            "url": null,
            "abstract": {
                "de": null,
                "en": null
            },
            "begin_planned": "2009-06-01T02:00:00+02:00",
            "begin_effective": "2011-03-01T01:00:00+01:00",
            "end_planned": "2009-11-30T01:00:00+01:00",
            "end_effective": "2011-09-30T02:00:00+02:00",
            "assignment": "2010-02-12T11:41:30+01:00",
            "program": null,
            "subprogram": null,
            "organization": 14014,
            "category": 10,
            "type": 10,
            "partner_function": 4,
            "manager": null,
            "contact": null,
            "status": 2,
            "research": 1,
            "grant": 10,
            "event": null,
            "study": null,
            "language": null,
            "funders": [
                457
            ],
            "funder_projectcode": null,
            "ethics_committee": null,
            "edudract_number": null,
            "persons": []
        },
        {
            "id": 1260,
            "title": {
                "de": "SFB: Mathematische Optimierung mit Anwendungen in der biomedizinischen Forschung\r\n1. Förderperiode",
                "en": "SFB: Mathematical Optimization with Applications in Biomedical Sciences"
            },
            "short": "Mathematical Optimization",
            "url": "http://math.uni-graz.at/mobis/",
            "abstract": {
                "de": "In this project, a realistic computer model of the heart, a “Virtual Heart” simulator will be developed to investigate mechanisms underlying the formation of arrhythmias, the most frequent cause of death in the industrialized world, and their termination by electrical shocks (electrical defibrillation). During the first phase, research will focus on different aspects of defibrillation with the goal to optimize the procedure to allow safe termination of arrhythmias with a fraction of energy requirements of current devices. For the first time, defibrillation will be formulated as an optimization problem using optimal control techniques to devise novel shock strategies. Further, techniques for the generation of microscopically accurate cardiac tissue models will be developed by applying novel strategies for segmentation and multi-modal registration  allowing the fusion of image stacks obtained with different imaging modalities (histological sections and MRI). To deal with the computational burden imposed by the resulting large systems (5-50 Mio dof), parallel algebraic MG and BEM/FEM coupling techniques will be applied to render parameters studies involving whole heart bidomain simulations including a torso possible.\r\nLong term goals include advanced techniques to optimize the exploration of complex parameter spaces associated with defibrillation with OPTIM, inverse methods will be considered to compute cardiac surface potentials from electrical or optical  recordings, and we will incorporate a mechanical contraction model and a fluid mechanical model to investigate electromechanical coupling and mechano-electrical feedback mechanisms and to link modelling results to clinically relevant quantities.",
                "en": "In this project, a realistic computer model of the heart, a “Virtual Heart” simulator will be developed to investigate mechanisms underlying the formation of arrhythmias, the most frequent cause of death in the industrialized world, and their termination by electrical shocks (electrical defibrillation). During the first phase, research will focus on different aspects of defibrillation with the goal to optimize the procedure to allow safe termination of arrhythmias with a fraction of energy requirements of current devices. For the first time, defibrillation will be formulated as an optimization problem using optimal control techniques to devise novel shock strategies. Further, techniques for the generation of microscopically accurate cardiac tissue models will be developed by applying novel strategies for segmentation and multi-modal registration  allowing the fusion of image stacks obtained with different imaging modalities (histological sections and MRI). To deal with the computational burden imposed by the resulting large systems (5-50 Mio dof), parallel algebraic MG and BEM/FEM coupling techniques will be applied to render parameters studies involving whole heart bidomain simulations including a torso possible.\r\nLong term goals include advanced techniques to optimize the exploration of complex parameter spaces associated with defibrillation with OPTIM, inverse methods will be considered to compute cardiac surface potentials from electrical or optical  recordings, and we will incorporate a mechanical contraction model and a fluid mechanical model to investigate electromechanical coupling and mechano-electrical feedback mechanisms and to link modelling results to clinically relevant quantities."
            },
            "begin_planned": "2006-12-01T01:00:00+01:00",
            "begin_effective": "2007-05-01T02:00:00+02:00",
            "end_planned": "2009-11-30T01:00:00+01:00",
            "end_effective": "2011-04-30T02:00:00+02:00",
            "assignment": "2007-05-09T13:44:14+02:00",
            "program": 67,
            "subprogram": null,
            "organization": 14011,
            "category": 10,
            "type": 10,
            "partner_function": 2,
            "manager": 50966,
            "contact": null,
            "status": 2,
            "research": 1,
            "grant": 10,
            "event": null,
            "study": null,
            "language": null,
            "funders": [
                9
            ],
            "funder_projectcode": "F32",
            "ethics_committee": null,
            "edudract_number": null,
            "persons": [
                "1260-50966-10",
                "1260-51753-12",
                "1260-51502-12",
                "1260-50967-12"
            ]
        },
        {
            "id": 1578,
            "title": {
                "de": "Whole Genome Screening des Menschen bei der Menigokokkensepsis",
                "en": "Whole Genome Screening des Menschen bei der Menigokokkensepsis"
            },
            "short": "Meningokokkensepsis",
            "url": null,
            "abstract": {
                "de": "Meningokokkenerkrankungen betreffen fast immer vorher vollkommen gesunde Kinder und können innerhalb weniger Stunden zum Tod führen. Die Erkrankung ist selten, in Österreich werden jährlich zwischen 80 und 100 Fälle beobachtet. Betroffen sind fast ausschließlich Kinder. Die septische Verlaufsform ist durch die rasche Entwicklung eines schweren Schocks mit verminderter Durchblutung der Haut, Bewusstlosigkeit, Multiorganversagen und schwerer Stö-rung der Blutgerinnung charakterisiert, die Sterblichkeit liegt trotz intensivmedizinischer Bemü-hungen noch immer bei etwa 25%.\r\nEs sind nun Genomanalysen verfügbar, mit denen das gesamte menschliche Genom (3 Mrd. Basenpaare) untersucht werden kann. Mit diesen neuen Methoden können alle genetischen Än-derungen, die für das Auftreten und den Verlauf einer Erkrankung verantwortlich sind, unter-sucht werden. In den letzten 2 Jahren sind bereits mehrere solche whole genome association studies (GWAs) veröffentlicht worden, jedoch wurden noch keine Ergebnisse zur Genetik der Sepsis gezeigt.\r\nMit Hilfe unseres Netzwerkes wäre es uns möglich, mit zwei weiteren Forschungsgruppen eine Kooperation zur Klärung der genetischen Ursachen der Meningokokkensepsis zu etablieren. Das so gebildete Kollektiv würde das weltweit größte Netzwerk zur Untersuchung von Meningo-kokkenerkrankungen darstellen. Es würde über 3000 europäischen Patienten sowie 700 Kon-trollproben umfassen und sich aus einer britischen, niederländischen, sowie unserer mitteleuro-päischen Kohorte zusammensetzen.\r\nIn Summe würden sich bei dem von uns primär eingesetzten Probenkollektiv von 200-400 Pati-enten  220 – 440 Millionen Einzeluntersuchungen zur Darstellung des gesamten Genoms jeder einzelnen Patienten- bzw. Kontrollprobe ergeben.\r\nDas Ziel dieser weltweiten Kooperation ist es, die genetischen Variablen, welche zu einer Me-ningokokkensepsis führen, aufzudecken. Es soll so eine erste komplette Übersicht über die Ge-netik der Sepsiserkrankung erreicht werden. Die Aufklärung der involvierten Gene kann als An-gelpunkt für die weiterführende Forschung gesehen werden und bildet eine erste Grundlage für die Entwicklung selektiver (Kombinations-) Therapien.",
                "en": "Meningokokkenerkrankungen betreffen fast immer vorher vollkommen gesunde Kinder und können innerhalb weniger Stunden zum Tod führen. Die Erkrankung ist selten, in Österreich werden jährlich zwischen 80 und 100 Fälle beobachtet. Betroffen sind fast ausschließlich Kinder. Die septische Verlaufsform ist durch die rasche Entwicklung eines schweren Schocks mit verminderter Durchblutung der Haut, Bewusstlosigkeit, Multiorganversagen und schwerer Stö-rung der Blutgerinnung charakterisiert, die Sterblichkeit liegt trotz intensivmedizinischer Bemü-hungen noch immer bei etwa 25%.\r\nEs sind nun Genomanalysen verfügbar, mit denen das gesamte menschliche Genom (3 Mrd. Basenpaare) untersucht werden kann. Mit diesen neuen Methoden können alle genetischen Än-derungen, die für das Auftreten und den Verlauf einer Erkrankung verantwortlich sind, unter-sucht werden. In den letzten 2 Jahren sind bereits mehrere solche whole genome association studies (GWAs) veröffentlicht worden, jedoch wurden noch keine Ergebnisse zur Genetik der Sepsis gezeigt.\r\nMit Hilfe unseres Netzwerkes wäre es uns möglich, mit zwei weiteren Forschungsgruppen eine Kooperation zur Klärung der genetischen Ursachen der Meningokokkensepsis zu etablieren. Das so gebildete Kollektiv würde das weltweit größte Netzwerk zur Untersuchung von Meningo-kokkenerkrankungen darstellen. Es würde über 3000 europäischen Patienten sowie 700 Kon-trollproben umfassen und sich aus einer britischen, niederländischen, sowie unserer mitteleuro-päischen Kohorte zusammensetzen.\r\nIn Summe würden sich bei dem von uns primär eingesetzten Probenkollektiv von 200-400 Pati-enten  220 – 440 Millionen Einzeluntersuchungen zur Darstellung des gesamten Genoms jeder einzelnen Patienten- bzw. Kontrollprobe ergeben.\r\nDas Ziel dieser weltweiten Kooperation ist es, die genetischen Variablen, welche zu einer Me-ningokokkensepsis führen, aufzudecken. Es soll so eine erste komplette Übersicht über die Ge-netik der Sepsiserkrankung erreicht werden. Die Aufklärung der involvierten Gene kann als An-gelpunkt für die weiterführende Forschung gesehen werden und bildet eine erste Grundlage für die Entwicklung selektiver (Kombinations-) Therapien."
            },
            "begin_planned": "2009-01-01T01:00:00+01:00",
            "begin_effective": "2008-07-17T02:00:00+02:00",
            "end_planned": "2009-10-31T01:00:00+01:00",
            "end_effective": "2010-05-31T02:00:00+02:00",
            "assignment": "2008-07-16T13:03:29+02:00",
            "program": null,
            "subprogram": null,
            "organization": 14091,
            "category": 10,
            "type": 10,
            "partner_function": 4,
            "manager": 51647,
            "contact": 54004,
            "status": 2,
            "research": 1,
            "grant": 10,
            "event": null,
            "study": null,
            "language": null,
            "funders": [
                135
            ],
            "funder_projectcode": null,
            "ethics_committee": null,
            "edudract_number": null,
            "persons": [
                "1578-51647-10"
            ]
        },
        {
            "id": 977,
            "title": {
                "de": "Mutation distribution and identification of novel genes in hereditary neuropathies",
                "en": "Mutation distribution and identification of novel genes in hereditary neuropathies"
            },
            "short": "GENETIK BEI HEREDITAEREN NEUROPATHIEN",
            "url": null,
            "abstract": {
                "de": "Hereditary neuropathies are one of the most frequently inherited causes of neurological disability with an estimated prevalence of 1 in 2500. Age at onset is usually during the first two decades of life or sometimes later. Molecular genetic examinations have shown marked genetic heterogenety with more than 30 genes identified. In some CMT patients and families the underlying gene still has to be found.\r\nIn this project we aim to recruit CMT patients and families in all parts of Austria. We will carry out detailed clinical, electrophysiological and genetic examinations and perform epidemiological studies. Further we aim to identify a novel gene locus in autosomal dominant HSN and MSN type 1.\r\nAnother important aim of this project is to utilize the already existing collaborations with other European groups to create a network with special focus on peripheral neuropathies.",
                "en": "Hereditary neuropathies are one of the most frequently inherited causes of neurological disability with an estimated prevalence of 1 in 2500. Age at onset is usually during the first two decades of life or sometimes later. Molecular genetic examinations have shown marked genetic heterogenety with more than 30 genes identified. In some CMT patients and families the underlying gene still has to be found.\r\nIn this project we aim to recruit CMT patients and families in all parts of Austria. We will carry out detailed clinical, electrophysiological and genetic examinations and perform epidemiological studies. Further we aim to identify a novel gene locus in autosomal dominant HSN and MSN type 1.\r\nAnother important aim of this project is to utilize the already existing collaborations with other European groups to create a network with special focus on peripheral neuropathies."
            },
            "begin_planned": "2006-11-01T01:00:00+01:00",
            "begin_effective": "2006-11-01T01:00:00+01:00",
            "end_planned": "2009-10-31T01:00:00+01:00",
            "end_effective": "2011-03-31T02:00:00+02:00",
            "assignment": "2006-12-27T12:44:35+01:00",
            "program": 72,
            "subprogram": null,
            "organization": 14080,
            "category": 10,
            "type": 10,
            "partner_function": 4,
            "manager": null,
            "contact": null,
            "status": 2,
            "research": 1,
            "grant": 10,
            "event": null,
            "study": null,
            "language": null,
            "funders": [
                9
            ],
            "funder_projectcode": "P19455",
            "ethics_committee": null,
            "edudract_number": null,
            "persons": [
                "977-51831-12"
            ]
        },
        {
            "id": 864,
            "title": {
                "de": "PREGENESYS: Development of Early Non-Invasive Biomarkers and Means for the Diagnosis and Progression Monitoring of Preeclampsia and Tailoring Putative Therapies",
                "en": "PREGENESYS: Development of Early Non-Invasive Biomarkers and Means for the Diagnosis and Progression Monitoring of Preeclampsia and Tailoring Putative Therapies"
            },
            "short": "PREGENESYS",
            "url": null,
            "abstract": {
                "de": "Preeclampsia (PET), de-novo hypertension & proteinuria after mid gestation, affects 5-7% of all pregnancies. Cases may develop life threatening haemolysis-elevated liver enzymes-low platelets (HELLP) or renal failure, cerebral haemorrhages & eclampsia, IUGR, placental abruption & death.\r\nWe will identify markers for PET risk prediction in the 1st trimester to allow longer time for tailoring putative medications to prevent PET, and assess & characterize plausible links between marker shortage/access, PET & putative medications in \"in-vitro\" systems to fit putative medications to pre-defined disease-risk women.\r\nWe will develop non-invasive diagnostic kits for 1st trimester PET prediction based on markers, antibodies, oligos & siRNA and others coupled to the power of Doppler ultrasound. Nested case-control clinical studies will test effectiveness of combined diagnosis & drug tailoring. A Trans European prospective clinical study, combining early diagnosis & randomising putative medication will verify findings.\r\nR&D results will be used to train physicians & patients, to implement new prenatal care practice and eradicate preeclampsia.",
                "en": "Preeclampsia (PET), de-novo hypertension & proteinuria after mid gestation, affects 5-7% of all pregnancies. Cases may develop life threatening haemolysis-elevated liver enzymes-low platelets (HELLP) or renal failure, cerebral haemorrhages & eclampsia, IUGR, placental abruption & death.\r\nWe will identify markers for PET risk prediction in the 1st trimester to allow longer time for tailoring putative medications to prevent PET, and assess & characterize plausible links between marker shortage/access, PET & putative medications in \"in-vitro\" systems to fit putative medications to pre-defined disease-risk women.\r\nWe will develop non-invasive diagnostic kits for 1st trimester PET prediction based on markers, antibodies, oligos & siRNA and others coupled to the power of Doppler ultrasound. Nested case-control clinical studies will test effectiveness of combined diagnosis & drug tailoring. A Trans European prospective clinical study, combining early diagnosis & randomising putative medication will verify findings.\r\nR&D results will be used to train physicians & patients, to implement new prenatal care practice and eradicate preeclampsia."
            },
            "begin_planned": "2006-10-01T02:00:00+02:00",
            "begin_effective": "2006-12-01T01:00:00+01:00",
            "end_planned": "2009-09-30T02:00:00+02:00",
            "end_effective": "2009-11-30T01:00:00+01:00",
            "assignment": "2006-08-07T16:55:01+02:00",
            "program": 21,
            "subprogram": "Biowissenschaften",
            "organization": 14017,
            "category": 10,
            "type": 10,
            "partner_function": 2,
            "manager": 54142,
            "contact": 54142,
            "status": 2,
            "research": 1,
            "grant": 10,
            "event": null,
            "study": null,
            "language": null,
            "funders": [
                10
            ],
            "funder_projectcode": null,
            "ethics_committee": null,
            "edudract_number": null,
            "persons": [
                "864-54142-10",
                "864-50278-12"
            ]
        },
        {
            "id": 1949,
            "title": {
                "de": "Smoking Genes",
                "en": "Smoking Genes"
            },
            "short": "SMOKING GENES",
            "url": null,
            "abstract": {
                "de": null,
                "en": null
            },
            "begin_planned": "2009-09-01T02:00:00+02:00",
            "begin_effective": "2009-09-01T02:00:00+02:00",
            "end_planned": "2009-09-30T02:00:00+02:00",
            "end_effective": "2009-09-30T02:00:00+02:00",
            "assignment": "2009-10-15T16:40:00+02:00",
            "program": null,
            "subprogram": "Generation Innovation Praktika",
            "organization": 14028,
            "category": 10,
            "type": 10,
            "partner_function": 4,
            "manager": 50910,
            "contact": 50910,
            "status": 2,
            "research": 5,
            "grant": 10,
            "event": null,
            "study": null,
            "language": null,
            "funders": [
                416
            ],
            "funder_projectcode": "824442",
            "ethics_committee": null,
            "edudract_number": null,
            "persons": [
                "1949-50910-10"
            ]
        },
        {
            "id": 1371,
            "title": {
                "de": "Interventionsprogramm für Eltern von Frühgeborenen; Eine Studie zur Optimierung der Entwicklung von Frühgeborenen",
                "en": "Interventionsprogramm für Eltern von Frühgeborenen; Eine Studie zur Optimierung der Entwicklung von Frühgeborenen"
            },
            "short": "INTERVENTIONSPROG_FRUEHGEBORENE",
            "url": null,
            "abstract": {
                "de": "In der Steiermark werden im Jahr ca. 9000 Kinder geboren. Davon kommen ca. 10 Prozent zu früh auf die Welt. Hinsichtlich Entwicklungsstörungen sind Kinder mit einem Geburtsgewicht von unter 1500g besonders gefährdet, der Fachausdruck für diese Kinder lautet \"very low birth weight infants\". Diese Kinder weisen im jungen Erwachsenenalter im Vergleich zu ehemals reif geborenen Neugeborenen, einen niedrigeren Schulabschluss und eine geringere durchschnittliche kognitive Leistung auf. Zusätzlich haben sie häufiger soziale Schwierigkeiten im Umgang mit Gleichaltrigen.\r\nIn der vorliegenden Studie wird der Entwicklungsverlauf kleiner Frühgeborener (FG<= 32.SSW) im Zusammenhang mit einer - zur psychologischen Einzelbetreuung zusätzlichen - Gruppenbetreuung und einer ambulanten bzw. mobilen psychologischen Einzelbetreuung derer Eltern beobachtet und gemessen. Gleichzeitig sollten das individuelle Stressniveau und die Kontrollüberzeugung und mögliche Veränderungen durch ein frühzeitig ambulant-mobiles Interventionsprogramm der Mütter/Eltern von FG erhoben werden.",
                "en": "In der Steiermark werden im Jahr ca. 9000 Kinder geboren. Davon kommen ca. 10 Prozent zu früh auf die Welt. Hinsichtlich Entwicklungsstörungen sind Kinder mit einem Geburtsgewicht von unter 1500g besonders gefährdet, der Fachausdruck für diese Kinder lautet \"very low birth weight infants\". Diese Kinder weisen im jungen Erwachsenenalter im Vergleich zu ehemals reif geborenen Neugeborenen, einen niedrigeren Schulabschluss und eine geringere durchschnittliche kognitive Leistung auf. Zusätzlich haben sie häufiger soziale Schwierigkeiten im Umgang mit Gleichaltrigen.\r\nIn der vorliegenden Studie wird der Entwicklungsverlauf kleiner Frühgeborener (FG<= 32.SSW) im Zusammenhang mit einer - zur psychologischen Einzelbetreuung zusätzlichen - Gruppenbetreuung und einer ambulanten bzw. mobilen psychologischen Einzelbetreuung derer Eltern beobachtet und gemessen. Gleichzeitig sollten das individuelle Stressniveau und die Kontrollüberzeugung und mögliche Veränderungen durch ein frühzeitig ambulant-mobiles Interventionsprogramm der Mütter/Eltern von FG erhoben werden."
            },
            "begin_planned": "2007-10-01T02:00:00+02:00",
            "begin_effective": "2007-10-01T02:00:00+02:00",
            "end_planned": "2009-09-30T02:00:00+02:00",
            "end_effective": "2010-09-30T02:00:00+02:00",
            "assignment": "2007-10-02T17:41:06+02:00",
            "program": null,
            "subprogram": null,
            "organization": 14094,
            "category": 10,
            "type": 10,
            "partner_function": 4,
            "manager": null,
            "contact": null,
            "status": 2,
            "research": 4,
            "grant": 10,
            "event": null,
            "study": null,
            "language": null,
            "funders": [],
            "funder_projectcode": null,
            "ethics_committee": null,
            "edudract_number": null,
            "persons": [
                "1371-50907-12",
                "1371-59859-11",
                "1371-51822-12",
                "1371-51643-11",
                "1371-51653-12"
            ]
        },
        {
            "id": 2033,
            "title": {
                "de": "Mit autologen Thrombozyten angereichertes körpereigenes Fibrin zur Förderung der Wundheilung bei chronischem Ulcus cruris venosum (kontrollierte prospektive randomisierte klinische Studie)",
                "en": "Mit autologen Thrombozyten angereichertes körpereigenes Fibrin zur Förderung der Wundheilung bei chronischem Ulcus cruris venosum (kontrollierte prospektive randomisierte klinische Studie)"
            },
            "short": " Ulcus cruris venosum Studie",
            "url": null,
            "abstract": {
                "de": null,
                "en": null
            },
            "begin_planned": "2008-10-01T02:00:00+02:00",
            "begin_effective": "2010-01-01T01:00:00+01:00",
            "end_planned": "2009-09-30T02:00:00+02:00",
            "end_effective": "2011-12-31T01:00:00+01:00",
            "assignment": "2010-01-12T17:36:20+01:00",
            "program": null,
            "subprogram": null,
            "organization": 14073,
            "category": 10,
            "type": 10,
            "partner_function": 4,
            "manager": 51612,
            "contact": 51612,
            "status": 2,
            "research": 2,
            "grant": 10,
            "event": null,
            "study": null,
            "language": null,
            "funders": [
                135
            ],
            "funder_projectcode": null,
            "ethics_committee": null,
            "edudract_number": null,
            "persons": [
                "2033-51612-10"
            ]
        },
        {
            "id": 1882,
            "title": {
                "de": "Analysis of drug-metabolizing enzyme polymorphisms for response to anthracycline-based neoadjuvant chemotherapy in breast cancer",
                "en": "Analysis of drug-metabolizing enzyme polymorphisms for response to anthracycline-based neoadjuvant chemotherapy in breast cancer"
            },
            "short": "CHEMOTHERAP_BREAST CANCER",
            "url": null,
            "abstract": {
                "de": "Breast cancer is the most common malignancy affecting women. It is the second leading cause of cancer-related death in Europe and the United States. Despite several improvements in early diagnosis, surgical techniques and hormone-, immune- and chemotherapy, this disease remains a threat to life for a large number of women. Moreover, providing individual treatment with low toxicity but maximum benefit is still an unsolved problem.\r\nNeoadjuvant chemotherapy using anthracycline-containing regimes is a standard therapy for patients with locally advanced breast cancer and is increasingly used for early-stage operable disease. The main goal of neoadjuvant chemotherapy is to eliminate potential micrometastasis, thus improving disease-free survial.\r\nPharmacogenetics is aimed at understanding and predicting an individual's drug response based upon genetic variation.\r\n\r\nIn this pharmacogenetic project we investigate a set of heritable genetic factors in drug-metabolizing enzymes that might predict drug-induced anti-tumor response and toxicity of anthracycline-based neoadjuvant therapy in breast cancer, based upon multigenetic analysis.",
                "en": "Breast cancer is the most common malignancy affecting women. It is the second leading cause of cancer-related death in Europe and the United States. Despite several improvements in early diagnosis, surgical techniques and hormone-, immune- and chemotherapy, this disease remains a threat to life for a large number of women. Moreover, providing individual treatment with low toxicity but maximum benefit is still an unsolved problem.\r\nNeoadjuvant chemotherapy using anthracycline-containing regimes is a standard therapy for patients with locally advanced breast cancer and is increasingly used for early-stage operable disease. The main goal of neoadjuvant chemotherapy is to eliminate potential micrometastasis, thus improving disease-free survial.\r\nPharmacogenetics is aimed at understanding and predicting an individual's drug response based upon genetic variation.\r\n\r\nIn this pharmacogenetic project we investigate a set of heritable genetic factors in drug-metabolizing enzymes that might predict drug-induced anti-tumor response and toxicity of anthracycline-based neoadjuvant therapy in breast cancer, based upon multigenetic analysis."
            },
            "begin_planned": "2009-05-01T02:00:00+02:00",
            "begin_effective": "2009-05-01T02:00:00+02:00",
            "end_planned": "2009-09-30T02:00:00+02:00",
            "end_effective": "2010-09-30T02:00:00+02:00",
            "assignment": "2009-08-03T14:52:33+02:00",
            "program": null,
            "subprogram": null,
            "organization": 14085,
            "category": 10,
            "type": 10,
            "partner_function": 4,
            "manager": 58814,
            "contact": 58814,
            "status": 2,
            "research": 1,
            "grant": 10,
            "event": null,
            "study": null,
            "language": null,
            "funders": [
                457
            ],
            "funder_projectcode": null,
            "ethics_committee": null,
            "edudract_number": null,
            "persons": [
                "1882-58814-10"
            ]
        },
        {
            "id": 1900,
            "title": {
                "de": "Genom und Autismus",
                "en": "Genom und Autismus"
            },
            "short": "GENOM_AUTISMUS",
            "url": null,
            "abstract": {
                "de": "Unser Konzept sieht vor, mit der etablierten Infrastruktur, bereits von Dr. Kaschnitz an der Universitätsklinik für Kinderheilkunde diagnostizierte Autismus PatientInnen gemäß den ADI (Autismus Diagnostik Interview)/ADOS (Diagnostische Beobachtungsskala für Autistische Störungen) Kriterien einzustufen, DNA aus peripherem Vollblut (ca. 5ml) zu isolieren und mittels modernster molekularer Methoden (Array-CGH) auf ASD-spezifische Kopienzahlvarianten (kleinste Verluste bzw. Zugewinne) im Erbgut zu untersuchen.",
                "en": "Unser Konzept sieht vor, mit der etablierten Infrastruktur, bereits von Dr. Kaschnitz an der Universitätsklinik für Kinderheilkunde diagnostizierte Autismus PatientInnen gemäß den ADI (Autismus Diagnostik Interview)/ADOS (Diagnostische Beobachtungsskala für Autistische Störungen) Kriterien einzustufen, DNA aus peripherem Vollblut (ca. 5ml) zu isolieren und mittels modernster molekularer Methoden (Array-CGH) auf ASD-spezifische Kopienzahlvarianten (kleinste Verluste bzw. Zugewinne) im Erbgut zu untersuchen."
            },
            "begin_planned": "2009-08-10T02:00:00+02:00",
            "begin_effective": "2009-08-10T02:00:00+02:00",
            "end_planned": "2009-09-04T02:00:00+02:00",
            "end_effective": "2009-09-04T02:00:00+02:00",
            "assignment": "2009-08-24T13:45:59+02:00",
            "program": null,
            "subprogram": "Generation Innovation Praktika",
            "organization": 14021,
            "category": 10,
            "type": 10,
            "partner_function": 4,
            "manager": 51996,
            "contact": 51996,
            "status": 2,
            "research": 2,
            "grant": 10,
            "event": null,
            "study": null,
            "language": null,
            "funders": [
                416
            ],
            "funder_projectcode": "824168",
            "ethics_committee": null,
            "edudract_number": null,
            "persons": [
                "1900-51996-10"
            ]
        },
        {
            "id": 978,
            "title": {
                "de": "Prostaglandin D2 als Mediator der Allergie",
                "en": "Prostaglandin D2 als Mediator der Allergie"
            },
            "short": "PROSTAGLANDIN_ALLERGIE",
            "url": null,
            "abstract": {
                "de": "Prostaglandin (PG) D2 is released by mast cells during the allergic response. Others and our group have recently produced considerable evidence that PGD2 might be involved in the initiation and perpetuation of allergic inflammation by orchestrating the recruitment of eosinophil granulocytes to the tissue, where they might cause tissue damage and induce the symptoms of allergic inflammation. The biological effects of PGD2 are mediated by three distinct receptors, the DP receptor, chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2), or at higher concentrations by the thromboxane receptor, TP. Small molecule antagonists of these receptors have recently become available and are currently being developed for the treatment of inflammatory diseases, such as bronchial asthma and eczema. However, the relative contributions of DP, CRTH2 and TP to PGD2-induced biological responses have still remained unclear, but the knowledge thereof is mandatory in order to predict which of these receptors are the most promising targets for the treatment of allergic disease and highlight their potential limitations. Eosinophil function will be investigated with respect to the release of eosinophils from the bone marrow, their recruitment into the tissue, the cells’ life span, and the release of pro-inflammatory mediators from eosinophils, such as reactive oxygen species, leukotrienes or exocytosed toxic granule contents. Moreover, we will test the potential clinical usefulness of CRTH2 and DP antagonists in vivo, using a murine model of ovalbumin-induced allergic pulmonary inflammation and airway hyperresponsiveness. Since the different biological responses to PGD2 can be mediated by CRTH2 or DP, respectively, a combined therapy with CRTH2 plus DP antagonists also needs to be given consideration. The study might hence lead to novel therapeutic regimens for the treatment of allergic inflammation and asthma.\r\n\r\n",
                "en": "Prostaglandin (PG) D2 is released by mast cells during the allergic response. Others and our group have recently produced considerable evidence that PGD2 might be involved in the initiation and perpetuation of allergic inflammation by orchestrating the recruitment of eosinophil granulocytes to the tissue, where they might cause tissue damage and induce the symptoms of allergic inflammation. The biological effects of PGD2 are mediated by three distinct receptors, the DP receptor, chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2), or at higher concentrations by the thromboxane receptor, TP. Small molecule antagonists of these receptors have recently become available and are currently being developed for the treatment of inflammatory diseases, such as bronchial asthma and eczema. However, the relative contributions of DP, CRTH2 and TP to PGD2-induced biological responses have still remained unclear, but the knowledge thereof is mandatory in order to predict which of these receptors are the most promising targets for the treatment of allergic disease and highlight their potential limitations. Eosinophil function will be investigated with respect to the release of eosinophils from the bone marrow, their recruitment into the tissue, the cells’ life span, and the release of pro-inflammatory mediators from eosinophils, such as reactive oxygen species, leukotrienes or exocytosed toxic granule contents. Moreover, we will test the potential clinical usefulness of CRTH2 and DP antagonists in vivo, using a murine model of ovalbumin-induced allergic pulmonary inflammation and airway hyperresponsiveness. Since the different biological responses to PGD2 can be mediated by CRTH2 or DP, respectively, a combined therapy with CRTH2 plus DP antagonists also needs to be given consideration. The study might hence lead to novel therapeutic regimens for the treatment of allergic inflammation and asthma."
            },
            "begin_planned": "2007-03-01T01:00:00+01:00",
            "begin_effective": "2007-05-01T02:00:00+02:00",
            "end_planned": "2009-08-31T02:00:00+02:00",
            "end_effective": "2011-03-31T02:00:00+02:00",
            "assignment": "2006-12-27T14:20:45+01:00",
            "program": 72,
            "subprogram": null,
            "organization": 14022,
            "category": 10,
            "type": 10,
            "partner_function": 4,
            "manager": 51756,
            "contact": 51756,
            "status": 2,
            "research": 1,
            "grant": 10,
            "event": null,
            "study": null,
            "language": null,
            "funders": [
                9
            ],
            "funder_projectcode": "P19424",
            "ethics_committee": null,
            "edudract_number": null,
            "persons": [
                "978-51832-12",
                "978-51756-10"
            ]
        },
        {
            "id": 1645,
            "title": {
                "de": "Influence of Antioxidative Agents like Resveratrol, Quercetin-dihydrate, and Seleno-L-Methionine on Human Synoviocytes of Osteoarthritis (OA), Rheumatoid Arthritis (RA) and Psoriasis Arthritis (PsA) Patients",
                "en": "Influence of Antioxidative Agents like Resveratrol, Quercetin-dihydrate, and Seleno-L-Methionine on Human Synoviocytes of Osteoarthritis (OA), Rheumatoid Arthritis (RA) and Psoriasis Arthritis (PsA) Patients"
            },
            "short": "Influence of Antioxidative Agents",
            "url": null,
            "abstract": {
                "de": "Osteoarthritis is the most prevalent disorder of the musculoskeletal system and has a very high socioeconomic impact. Current treatments for Osteoarthritis are only symptomatic, because they do not act on the causes of Arthritis and do not stop the progression of the disease. This study is designed to investigate the effect of Resveratrol, Quercetin, and Selenium on healthy human synovial cells compared to synovial cells from OA and RA patients. We propose that these chemo preventive agents cause a growth rate decrease in synovial tissue and furthermore an inhibition of proinflammatory factors as well as an increase in factors favouring apoptosis and cell death. \r\nEspecially Resveratrol is known as a potent specific inhibitor of inflammation, but its potency has not been tested on human synovial cells. If the potency in decreasing inflammatory Interleukins is similar to the results of animal experiments, it would be an enormous effort for treatment of Osteoarthritis and Rheumatoid Arthritis. This study should be undertaken to define a possible systemic or local application of Resveratrol compared to Quercetin and Selenium. A close interaction between clinicians and basic scientists is necessary because of the combination of analytical, functional and molecular methods.\r\n",
                "en": "Osteoarthritis is the most prevalent disorder of the musculoskeletal system and has a very high socioeconomic impact. Current treatments for Osteoarthritis are only symptomatic, because they do not act on the causes of Arthritis and do not stop the progression of the disease. This study is designed to investigate the effect of Resveratrol, Quercetin, and Selenium on healthy human synovial cells compared to synovial cells from OA and RA patients. We propose that these chemo preventive agents cause a growth rate decrease in synovial tissue and furthermore an inhibition of proinflammatory factors as well as an increase in factors favouring apoptosis and cell death. \r\nEspecially Resveratrol is known as a potent specific inhibitor of inflammation, but its potency has not been tested on human synovial cells. If the potency in decreasing inflammatory Interleukins is similar to the results of animal experiments, it would be an enormous effort for treatment of Osteoarthritis and Rheumatoid Arthritis. This study should be undertaken to define a possible systemic or local application of Resveratrol compared to Quercetin and Selenium. A close interaction between clinicians and basic scientists is necessary because of the combination of analytical, functional and molecular methods.\r\n"
            },
            "begin_planned": "2008-09-01T02:00:00+02:00",
            "begin_effective": "2008-08-01T02:00:00+02:00",
            "end_planned": "2009-08-31T02:00:00+02:00",
            "end_effective": "2010-08-31T02:00:00+02:00",
            "assignment": "2008-10-29T16:01:05+01:00",
            "program": 79,
            "subprogram": null,
            "organization": 14052,
            "category": 10,
            "type": 10,
            "partner_function": 4,
            "manager": null,
            "contact": null,
            "status": 2,
            "research": 1,
            "grant": 10,
            "event": null,
            "study": null,
            "language": null,
            "funders": [
                12
            ],
            "funder_projectcode": null,
            "ethics_committee": null,
            "edudract_number": null,
            "persons": [
                "1645-50696-12",
                "1645-57343-12"
            ]
        },
        {
            "id": 2008,
            "title": {
                "de": "Ganganalysen bei Kindern mit Morbus Perthes",
                "en": "Ganganalysen bei Kindern mit Morbus Perthes"
            },
            "short": "Morbus Perthes",
            "url": null,
            "abstract": {
                "de": null,
                "en": null
            },
            "begin_planned": "2009-04-01T02:00:00+02:00",
            "begin_effective": "2009-04-01T02:00:00+02:00",
            "end_planned": "2009-08-31T02:00:00+02:00",
            "end_effective": "2012-07-31T02:00:00+02:00",
            "assignment": "2009-12-04T11:57:57+01:00",
            "program": null,
            "subprogram": "Land Steiermark Abteilung 3",
            "organization": 14049,
            "category": 10,
            "type": 10,
            "partner_function": 4,
            "manager": 65038,
            "contact": 65038,
            "status": 2,
            "research": 2,
            "grant": 10,
            "event": null,
            "study": null,
            "language": null,
            "funders": [
                135
            ],
            "funder_projectcode": null,
            "ethics_committee": null,
            "edudract_number": null,
            "persons": [
                "2008-65038-10"
            ]
        },
        {
            "id": 1398,
            "title": {
                "de": "Neue Methode zur Beschleunigung der Knochenbruchheilung unter Zuhilfenahme von bioaktivem Glas, das mit Protein/Lipid-Peroxidationsprodukten beschichtet ist",
                "en": "Neue Methode zur Beschleunigung der Knochenbruchheilung unter Zuhilfenahme von bioaktivem Glas, das mit Protein/Lipid-Peroxidationsprodukten beschichtet ist"
            },
            "short": "KNOCHENBRUCHHEILUNG_BIOAKTIV_GAS",
            "url": null,
            "abstract": {
                "de": "Fractures of long bones or large joints are followed by long lasting and often incomplete recovery in particular in elderly people and patients with multifragmentary fractures. Hoping to solve this difficult medical and social problem various experimental treatments are being developed using bioactive materials or substances that may stimulate bone growth.\r\n\r\nOn the contrary, patients with traumatic brain injury exert very short period of bone healing. Our clinical studies and the use of genuine model of human bone tissue cultures indicated that such enhanced osteogenesis is associated with the complex stress response involving lipid peroxidation. Studying molecular mechanisms of this phenomenon we found that the product of lipid peroxidation 4-hydroxynonenal (HNE) may regulate the growth of cultured human bone cells.\r\n\r\nTherefore, the aim of this project is to study in vitro possible use of HNE applied on bioactive glass for promotion of osteogenesis.",
                "en": "Fractures of long bones or large joints are followed by long lasting and often incomplete recovery in particular in elderly people and patients with multifragmentary fractures. Hoping to solve this difficult medical and social problem various experimental treatments are being developed using bioactive materials or substances that may stimulate bone growth.\r\n\r\nOn the contrary, patients with traumatic brain injury exert very short period of bone healing. Our clinical studies and the use of genuine model of human bone tissue cultures indicated that such enhanced osteogenesis is associated with the complex stress response involving lipid peroxidation. Studying molecular mechanisms of this phenomenon we found that the product of lipid peroxidation 4-hydroxynonenal (HNE) may regulate the growth of cultured human bone cells.\r\n\r\nTherefore, the aim of this project is to study in vitro possible use of HNE applied on bioactive glass for promotion of osteogenesis."
            },
            "begin_planned": "2007-09-01T02:00:00+02:00",
            "begin_effective": "2007-09-01T02:00:00+02:00",
            "end_planned": "2009-08-31T02:00:00+02:00",
            "end_effective": "2009-08-31T02:00:00+02:00",
            "assignment": "2007-11-08T11:29:56+01:00",
            "program": 79,
            "subprogram": null,
            "organization": 14052,
            "category": 10,
            "type": 10,
            "partner_function": 4,
            "manager": null,
            "contact": null,
            "status": 2,
            "research": 2,
            "grant": 10,
            "event": null,
            "study": null,
            "language": null,
            "funders": [
                12
            ],
            "funder_projectcode": null,
            "ethics_committee": null,
            "edudract_number": null,
            "persons": []
        },
        {
            "id": 824,
            "title": {
                "de": "Geschlechtsspezifische Genexpresssion in Makrophagen",
                "en": "Differences in gender-specific gene expression in human and murine macrophages and foam cells"
            },
            "short": "Genexpresssion in Makrophagen",
            "url": null,
            "abstract": {
                "de": "Herz-Kreislauferkrankungen stellen in westlichen Zivilisationen Massenerkrankungen dar. Mit ca. 15 Mio. Todesfällen pro Jahr sterben ungefähr doppelt so viele Menschen weltweit an kardiovaskulären Erkrankungen wie Herzinfarkt und Gehirnschlag als an Krebs. \r\nMänner haben gegenüber Frauen eine 5-fach höhere Disposition für kardiovaskuläre Erkrankungen, was nicht alleine durch Rauchen, Fettleibigkeit, Bluthochdruck, Diabetes und erhöhte Cholesterinwerte erklärt werden kann. Die Wirkung von Geschlechtshormonen auf die Atherogenese ist sehr komplex, mit unterschiedlich starken Effekten von Östrogenen und Androgenen in weiblichen und männlichen Zellen. Höchstwahrscheinlich gibt es noch eine Vielzahl unbekannter Gene, die in der geschlechtsspezifischen Entstehung von Atherosklerose eine Rolle spielen. Erstaunlicherweise haben bislang nur wenige Studien geschlechtsspezifische Genexpressionen in Makrophagen und Schaumzellen untersucht.\r\nDas Ziel des vorliegenden Projekts ist die Identifizierung und funktionelle Charakterisierung von Genen, die in männlichen und weiblichen Makrophagen und Schaumzellen unterschiedlich stark exprimiert sind. Nach Identifizierung soll die Wirkung von Geschlechtshormonen auf die unterschiedliche Expression dieser Kandidatengene untersucht werden. Das Projekt zielt auf die Beantwortung der folgenden spezifischen Fragen: \r\n•) Welche Gene werden in männlichen und weiblichen Makrophagen und Schaumzellen des Menschen unterschiedlich stark exprimiert?\r\n•) Welche Gene werden in männlichen und weiblichen Makrophagen und Schaumzellen der Maus unterschiedlich stark exprimiert?\r\n•) Werden diese Gene durch Geschlechtshormone unterschiedlich reguliert?\r\n•) Was ist die Funktion dieser Gene?\r\nDurch Analysen mittels Microchip-Technologie und Bioinformatik sollen Zielgene identifiziert, ihre Regulation durch Geschlechtshormone untersucht, ihr Expressionsmuster in anderen relevanten Zellen und Geweben bestimmt und ihre biochemischen Eigenschaften charakterisiert werden. \r\nDieses Projekt soll einen Beitrag zum Verständnis der geschlechtsspezifischen Unterschiede bei der Entstehung von Atherosklerose leisten.\r\n",
                "en": "Studies on coronary heart disease demonstrate a sex-specific difference in its incidence and severity. The higher prevalence of hypertension, hypercholesterolemia, hyperglycemia, smoking and obesity in men does not suffice to explain the significant gender difference in cardiovascular risk. Thus male gender is one of the 5 dominating risk factors for atherosclerosis and coronary heart disease. The actions of sex hormones on atherogenesis are very complex, with different effects of estrogens or androgens on male or female cells. It is likely that there are many as yet unknown genes involved in the sex-specificity of the atherosclerotic process. To date, surprisingly few studies have addressed gender-related differences in macrophages and foam cells.\r\nThis project aims at discovering and functionally characterizing genes that are differentially expressed in male and female macrophages and foam cells. To determine target genes, gene expression profiling of human and murine macrophages and foam cells will be performed. The effects of sex steroid hormones on candidate gene expression levels in those cells will be investigated. Specifically, the following questions will be addressed:\r\n• Which genes are differentially expressed in human male and female macrophages and foam cells?\r\n• Which genes are differentially expressed in murine male and female macrophages and foam cells?\r\n• Are these genes differentially regulated by various sex steroid hormones? \r\n• What is the function of these genes? \r\nI expect to identify genes that are expressed in a gender-specific manner. The regulation of up- and downregulated target genes in macrophages and foam cells by various sex steroid hormones will be investigated. Products of candidate genes will be characterized in their biochemical function and their potential role in cholesterol metabolism. The results of the proposed project are expected to contribute to the understanding of gender-specific differences in atherogenesis. \r\n"
            },
            "begin_planned": "2006-09-01T02:00:00+02:00",
            "begin_effective": "2006-09-01T02:00:00+02:00",
            "end_planned": "2009-08-31T02:00:00+02:00",
            "end_effective": "2011-08-31T02:00:00+02:00",
            "assignment": "2006-05-16T17:27:25+02:00",
            "program": 72,
            "subprogram": null,
            "organization": 14013,
            "category": 10,
            "type": 10,
            "partner_function": 4,
            "manager": 51904,
            "contact": 51904,
            "status": 2,
            "research": 1,
            "grant": 10,
            "event": null,
            "study": null,
            "language": null,
            "funders": [
                9
            ],
            "funder_projectcode": "P19186",
            "ethics_committee": null,
            "edudract_number": null,
            "persons": [
                "824-51904-10"
            ]
        },
        {
            "id": 1906,
            "title": {
                "de": "Hochdurchsatz-Genexpressionsanalyse in distinkten Hirnregionen verhaltensdivergenter Rattenstämme in Abhängigkeit von Stressexposition und Geschlechtszugehörigkeit",
                "en": "High throughput gene expression analysis in the brain of behaviourally divergent rat strains under the influence of stress exposure and gender"
            },
            "short": "Stressexposition und Geschlecht",
            "url": null,
            "abstract": {
                "de": "Die Begriffe \"stress\" und \"burnout\" sind mittlerweile sprachliches Gemeingut, ihre biomedizinische Bedeutung ist aber, aufgrund nach wie vor fehlender basaler molekularer Konzepte, keineswegs vollständig erfassbar, was allerdings im Sinne adäquater, effizienter Therapieansätze unbedingt nötig wäre.\r\nZur Analyse der möglichen genetischen Determination individueller, wie auch geschlechtsspezifischer Stress-Suszeptibilität wurden bisher stets Tiermodelle herangezogen, in denen a priori definierte Parameter, wie die Expression bekannter Transkriptionsverfahren oder Neurotransmitter als Maß selektiver neuronaler Akrivierung dienten.\r\nDem gegenüber zielt das vorliegende Projektvorhaben darauf ab, innerhalb eines etablierten tierexperimentellen psychologischen Stressmodells, in einem Hochdurchsatz-Prozess mittels automatisierter whole transcriptome analysis durch Microarray-Technologie simultan die Gesamtheit aller stressaktiviertern Gene in bekannten Stresszentren des Gehirns zu erfassen. \r\nAufgrund von bereits erfolgten technischen Vorstudien darf von den Resultaten dieser Studie erwartet werden, wertvolle neue wissenschaftliche Stossrichtungen bezüglich der Aufklärung molekularer Mechanismen geschlechtsspezifischer, Stress-Antwort des Gehirns zu eröffnen.",
                "en": "Die Begriffe \"stress\" und \"burnout\" sind mittlerweile sprachliches Gemeingut, ihre biomedizinische Bedeutung ist aber, aufgrund nach wie vor fehlender basaler molekularer Konzepte, keineswegs vollständig erfassbar, was allerdings im Sinne adäquater, effizienter Therapieansätze unbedingt nötig wäre.\r\nZur Analyse der möglichen genetischen Determination individueller, wie auch geschlechtsspezifischer Stress-Suszeptibilität wurden bisher stets Tiermodelle herangezogen, in denen a priori definierte Parameter, wie die Expression bekannter Transkriptionsverfahren oder Neurotransmitter als Maß selektiver neuronaler Akrivierung dienten.\r\nDem gegenüber zielt das vorliegende Projektvorhaben darauf ab, innerhalb eines etablierten tierexperimentellen psychologischen Stressmodells, in einem Hochdurchsatz-Prozess mittels automatisierter whole transcriptome analysis durch Microarray-Technologie simultan die Gesamtheit aller stressaktiviertern Gene in bekannten Stresszentren des Gehirns zu erfassen. \r\nAufgrund von bereits erfolgten technischen Vorstudien darf von den Resultaten dieser Studie erwartet werden, wertvolle neue wissenschaftliche Stossrichtungen bezüglich der Aufklärung molekularer Mechanismen geschlechtsspezifischer, Stress-Antwort des Gehirns zu eröffnen."
            },
            "begin_planned": "2009-07-01T02:00:00+02:00",
            "begin_effective": "2009-10-01T02:00:00+02:00",
            "end_planned": "2009-08-30T02:00:00+02:00",
            "end_effective": "2011-07-31T02:00:00+02:00",
            "assignment": "2009-09-02T17:58:02+02:00",
            "program": null,
            "subprogram": null,
            "organization": 14014,
            "category": 10,
            "type": 10,
            "partner_function": 4,
            "manager": 51205,
            "contact": 51205,
            "status": 2,
            "research": 1,
            "grant": 10,
            "event": null,
            "study": null,
            "language": null,
            "funders": [
                135
            ],
            "funder_projectcode": null,
            "ethics_committee": null,
            "edudract_number": null,
            "persons": [
                "1906-51205-10"
            ]
        },
        {
            "id": 1328,
            "title": {
                "de": "Type-I Diabetes Mellitus in Early Pregnancy: Effect on Placental Development",
                "en": "Type-I Diabetes Mellitus in Early Pregnancy: Effect on Placental Development"
            },
            "short": "DIABETES_MELLITUS_EARLY_PREGNANCY",
            "url": null,
            "abstract": {
                "de": "Diabetes anfangs der Schwangerschaft ist of verbunden mit einer Wachstumsverzögerung der Kinder, wahrscheinlich wegen eines verzögerten Wachstums des Mutterkuchens (Plazenta). Es gibt Hinweise, dass hohe Glukosekonzentrationen des Diabetes das Wachstum von Plazentazellen verändern. Im Projekt wird Plazentagewebe von gesunden und Typ-1 diabetischen Müttern untersucht, die in der 6.-12. Woche ihre Schwangerschaft beendeten. Ergänzend werden isolierte Plazentazellen unter Diabetes-ähnlichen Bedingungen (hohe Glukosekonzentration-veränderte Proteine) kultiviert und diverse Parameter gemessen, die verbunden sind mit Zellwachstum und Zelltod. Dies wird Aufschluss geben, ob die Reduktion des Plazentawachstums auf eine Abnahme der Teilungsaktivität oder eine Zunahme des Zelltodes der Plazentazellen zurückzuführen ist und die Rolle von Glukose dabei. Das Projekt wird zeigen, wie mütterlicher Diabetes am Anfang der Schwangerschaft das Wachstum der Plazenta und damit des Kindes beeinflusst.",
                "en": "Diabetes anfangs der Schwangerschaft ist of verbunden mit einer Wachstumsverzögerung der Kinder, wahrscheinlich wegen eines verzögerten Wachstums des Mutterkuchens (Plazenta). Es gibt Hinweise, dass hohe Glukosekonzentrationen des Diabetes das Wachstum von Plazentazellen verändern. Im Projekt wird Plazentagewebe von gesunden und Typ-1 diabetischen Müttern untersucht, die in der 6.-12. Woche ihre Schwangerschaft beendeten. Ergänzend werden isolierte Plazentazellen unter Diabetes-ähnlichen Bedingungen (hohe Glukosekonzentration-veränderte Proteine) kultiviert und diverse Parameter gemessen, die verbunden sind mit Zellwachstum und Zelltod. Dies wird Aufschluss geben, ob die Reduktion des Plazentawachstums auf eine Abnahme der Teilungsaktivität oder eine Zunahme des Zelltodes der Plazentazellen zurückzuführen ist und die Rolle von Glukose dabei. Das Projekt wird zeigen, wie mütterlicher Diabetes am Anfang der Schwangerschaft das Wachstum der Plazenta und damit des Kindes beeinflusst."
            },
            "begin_planned": "2007-09-01T02:00:00+02:00",
            "begin_effective": "2007-09-01T02:00:00+02:00",
            "end_planned": "2009-08-30T02:00:00+02:00",
            "end_effective": "2011-08-31T02:00:00+02:00",
            "assignment": "2007-07-10T12:30:06+02:00",
            "program": 79,
            "subprogram": null,
            "organization": 14038,
            "category": 10,
            "type": 10,
            "partner_function": 4,
            "manager": 51632,
            "contact": 51632,
            "status": 2,
            "research": 1,
            "grant": 10,
            "event": null,
            "study": null,
            "language": null,
            "funders": [
                12
            ],
            "funder_projectcode": null,
            "ethics_committee": null,
            "edudract_number": null,
            "persons": [
                "1328-51632-10"
            ]
        },
        {
            "id": 1000,
            "title": {
                "de": "EMERGE: Emergency Monitoring and Prevention",
                "en": "EMERGE: Emergency Monitoring and Prevention"
            },
            "short": "EMERGE",
            "url": null,
            "abstract": {
                "de": "Die Verbesserung der Lebensqualität von älteren Menschen und vor allem die Möglichkeit dass sie länger in ihrer vertrauten Umgebung leben können, ist eine immer wichtigere Aufgabe für Forschung und Entwicklung in unserer Informationsgesellschaft. Demografische Entwicklungen prognostizieren mit hoher Zuverlässigkeit eine enorme Zunahme der älteren Bevölkerung in der Zukunft. Neue Technologien, vor allem so genannte Ambient Intelligence Technologien, wecken die Hoffnung nach vielfältiger und umfassender Unterstützung im alltäglichen Leben. Vor allem ist könnten damit ältere Menschen in Notsituationen zu unterstützt oder sogar vor Notsituationen bewahrt werden. Allerdings ist der Umgang mit Informationstechnologie gerade für ältere Menschen nicht immer einfach. Überforderung, Misstrauen, Angst und letztendlich Ablehnung solcher technologischen Hilfen ist daher zu befürchten. Das liegt nicht immer nur an körperlicher oder kognitiver Einschränkung, sondern oft in der Komplexität solcher Systeme. Besonders deutlich werden diese Probleme bei der Gesundheitsüberwachung. Schließlich ist das eine Chance, dass ältere Menschen länger in ihrer vertrauten Umgebung bleiben können, was schließlich auch Kosten reduziert und die Lebensqualität erhöht.\r\nDiesen Herausforderungen stellt sich ein Konsortium bestehend aus 9 Partnern im\r\nForschungsprojekt EMERGE (Emergency Monitoring and Prevention), gefördert aus dem\r\nAmbient Assisted Living Programm der Europäischen Union: Fraunhofer-Gesellschaft,\r\nWestpfalz-Klinikum, Siemens AG, Microsoft European Innovation Center (alle Deutschland), Art of Technology (Schweiz), NCSR Demokritos, e-ISOTIS (Griechenland), Bay Zoltan Foundation (Ungarn) und die medizinische Universität Graz (Österreich). Hauptkoordinator ist das renommierte Fraunhofer Institut für Experimentelles Software Engineering (IESE). Ziel des Projektes ist die Nutzung ambienter, möglichst unauffälliger Sensoren in einem Lebensassistenzsystem, um unaufdringlich einen Überblick über Aktivitäten und Bewegungen zu gewinnen, daraus lebenswichtige Daten zu sammeln, mit dem Ziel in Notsituationen rasch\r\nhelfen zu können. Durch die gewonnenen Informationen über die täglichen Routine der\r\nZielgruppe älterer Personen vor allem mit medizinischen Risiken sollen Trends ermittelt und Abweichungen erkannt werden (Human-Capability Model), um nicht nur rasch, sondern auch frühzeitig reagieren zu können. Die Sichtweise auf solche in Notsituationen unterstützende Systeme ist dabei ganzheitlich, sie sollen exakt auf die Bedürfnisse der jeweiligen End-Benutzerinnen und End-Benutzer in der gesamten Nutzerkette (Patienten – Mediziner – Rettungsdienste) angepasst werden können. Die Forschungseinheit HCI4MED am Institut für medizinische Informatik, Statistik und Dokumentation (IMI) der Medizinischen Universität Graz (MUG) integriert – zusätzlich zu den technologischen Aspekten – benutzerzentrierte und kognitionspsychologische Aspekte medizinischer Informationsverarbeitung und ist innerhalb von EMERGE verantwortlich für die Themen Mensch–Maschine Kommunikation, Usability\r\nEngineering und lebensbegleitendes Lernen (Life-Long Learning).",
                "en": "Improving the quality of life of elderly people is an emerging issue within our information society for both research and development. Demographical changes in Europe lead us to expect that the percentage of older people within the population will continue to increase in the future. New Technologies, including ambient intelligence technologies, awaken the hope of ubiquitous support in daily life. Most of all, there is a necessity to protect the elderly from emergency situations where possible and to provide rapid assistance when this is not possible. Basically, the use of technology is not always easy, however, elderly people are confronted with a number of additional problems due to its complexity. Further problems are often\r\ncaused by physical and/or cognitive impairment. Distrust, fear, anxiety and consequently frequent rejection of technology must be taken into consideration. A currently acute issue is that of delayed calls to emergency medical services, which can lead to increased hospitalization and the necessity for elderly people to move into nursing homes, consequently unnecessarily decreasing their quality of life and also involving considerable expenditure.\r\nThese challenges are addressed in the EMERGE (EMERGEncy Monitoring and Prevention) project. The approach is to use ambient and unobtrusive sensors to monitor activity, location, and vital data. Daily routine can be tracked in order to detect abnormalities and to create early indicators for potentially arising trends and emergencies in advance. One goal is to recognize emergency situations at home with the help of ambient and unobtrusive technology, to develop a Human-Capability Model and to provide adequate assistance when needed. In addition to technological solutions, models for complete systems will be developed, which include the personal environment as well as recorded sensor data and which can be customtailored\r\nexactly to the needs of the end users. The impact of the developed prototypical\r\nsolution on quality of life will be measured in an Assisted Living Laboratory and in a\r\nmultinational site evaluation. It is expected that EMERGE will help elderly people to live a safer, self-determined life and to stay longer in their preferred environment. The EMERGE consortium consists of 9 European partners: Westpfalz-Klinikum, Kaiserslautern; Siemens AG; Microsoft European Innovation Center (all Germany), Art of Technology, Switzerland, NCSR Demokritos and e-ISOTIS (both Greece); Bay Zoltan Foundation, Hungary and Medical University Graz (Austria). The main coordinator is the Fraunhofer Institute for Experimental Software Engineering (IESE). Within EMERGE, the Medical University Graz (MUG) is responsible for the areas Human–Computer Interaction, Usability Engineering and Life-Long Learning. Research within the HCI4MED area of the Institute of Medical Informatics Statistics and Documentation (IMI) integrates – in addition to the necessary\r\ntechnological aspects – human-centered, cognitive aspects of medical information processing."
            },
            "begin_planned": "2007-02-01T01:00:00+01:00",
            "begin_effective": "2007-02-01T01:00:00+01:00",
            "end_planned": "2009-07-31T02:00:00+02:00",
            "end_effective": "2010-01-31T01:00:00+01:00",
            "assignment": "2007-01-15T14:20:24+01:00",
            "program": 21,
            "subprogram": "Ambient Assisted Living and Life Long Learning Support",
            "organization": 14026,
            "category": 10,
            "type": 10,
            "partner_function": 2,
            "manager": 51050,
            "contact": 51050,
            "status": 2,
            "research": 3,
            "grant": 10,
            "event": null,
            "study": null,
            "language": null,
            "funders": [
                10
            ],
            "funder_projectcode": null,
            "ethics_committee": null,
            "edudract_number": null,
            "persons": [
                "1000-54223-12",
                "1000-51050-10",
                "1000-52966-12"
            ]
        },
        {
            "id": 1722,
            "title": {
                "de": "Determining the Hierarchy of EMTRs in Malignant Melanoma",
                "en": "Determining the Hierarchy of EMTRs in Malignant Melanoma"
            },
            "short": "DETERMINING_HIERARCHY_EMTR_MELANOMA",
            "url": null,
            "abstract": {
                "de": "Epithelial-mesenchymal transition (EMT) is a hallmark of cellular transformation in solid tumors. A similar process is thought to be relevant for melanomgenesis. The exact mechanisms how this is accomplished with respect to stage specific effects of epilthelial-mesenchymal transcriptional regulation, however, are unknown for many tumor entities and melanoma in particular. \r\nThe intent of this project is to decipher targets of EMT inducing regulators at the transcriptional level as exemplified by modulation of cadherins through hepatocyte growth factor (HGF), an important growth factor in melanomagenesis. Our previous data show that the effect of HGF on epithelial-mesenchymal transcriptional regulators (EMTRs) is stage-dependent in melanoma cell lines. Based on these observations we want to pinpoint EMTRs specific binding to E-boxes in cadherins, investigate on HGF-mediated regulation of Snail and Slug and study overexpression of Slug and Twist in melanoma cell lines. We expect to uncover the hierachical sequence of EMTRs activation in early versus late stage melanomas, the preferential binding of EMRTs to cadherins and in vitro and in vivo effects of over-expressed or down-regulated EMRTs. The following hypothesis:\r\n\"Hierachy of epithelial-mesenchymal transcriptional regulators in malignant melanoma\"\r\nwill be tested in two specific aims:\r\n*Continuing investigations on E-box binding EMRTs and the functional effects of Slug and Twist in melanocytic cells \r\n*Scrutinizing HGF mediated modulation of Snail, Slug and Twist through regulation by NF-kB and GSK -3ß.",
                "en": "Epithelial-mesenchymal transition (EMT) is a hallmark of cellular transformation in solid tumors. A similar process is thought to be relevant for melanomgenesis. The exact mechanisms how this is accomplished with respect to stage specific effects of epilthelial-mesenchymal transcriptional regulation, however, are unknown for many tumor entities and melanoma in particular. \r\nThe intent of this project is to decipher targets of EMT inducing regulators at the transcriptional level as exemplified by modulation of cadherins through hepatocyte growth factor (HGF), an important growth factor in melanomagenesis. Our previous data show that the effect of HGF on epithelial-mesenchymal transcriptional regulators (EMTRs) is stage-dependent in melanoma cell lines. Based on these observations we want to pinpoint EMTRs specific binding to E-boxes in cadherins, investigate on HGF-mediated regulation of Snail and Slug and study overexpression of Slug and Twist in melanoma cell lines. We expect to uncover the hierachical sequence of EMTRs activation in early versus late stage melanomas, the preferential binding of EMRTs to cadherins and in vitro and in vivo effects of over-expressed or down-regulated EMRTs. The following hypothesis:\r\n\"Hierachy of epithelial-mesenchymal transcriptional regulators in malignant melanoma\"\r\nwill be tested in two specific aims:\r\n*Continuing investigations on E-box binding EMRTs and the functional effects of Slug and Twist in melanocytic cells \r\n*Scrutinizing HGF mediated modulation of Snail, Slug and Twist through regulation by NF-kB and GSK -3ß."
            },
            "begin_planned": "2008-08-01T02:00:00+02:00",
            "begin_effective": "2009-01-15T01:00:00+01:00",
            "end_planned": "2009-07-31T02:00:00+02:00",
            "end_effective": "2011-01-14T01:00:00+01:00",
            "assignment": "2009-01-16T14:06:24+01:00",
            "program": 72,
            "subprogram": null,
            "organization": 14047,
            "category": 10,
            "type": 10,
            "partner_function": 4,
            "manager": 53662,
            "contact": 53662,
            "status": 2,
            "research": 5,
            "grant": 10,
            "event": null,
            "study": null,
            "language": null,
            "funders": [
                9
            ],
            "funder_projectcode": "P21156",
            "ethics_committee": null,
            "edudract_number": null,
            "persons": [
                "1722-53662-10"
            ]
        }
    ]
}